Cagrilintide vs Semaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicCagrilintideSemaglutide
What it is

An investigational long-acting amylin analogue from Novo Nordisk, also known as AM833.1,8

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.4

FDA status

In clinical trials

In clinical trials; not FDA-approved1,2,3

Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.3

Is cagrilintide FDA-approved?

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy4,5,6,7

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.4,5,6,7

Is semaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.9

Not among the six peptides the policy lists.9

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial A 26-week randomized Phase 2 trial comparing several cagrilintide groups in 706 adults without diabetes, with placebo and liraglutide comparison groups, published in The Lancet.8
  • Large randomized human trial REDEFINE 1, a 68-week randomized Phase 3a trial in 3,417 adults with overweight or obesity that compared the cagrilintide-semaglutide combination with each component alone and with placebo, published in The New England Journal of Medicine.10
  • Registered trial without results A Phase 3 trial of cagrilintide alone in people with overweight or obesity and type 2 diabetes (NCT07220759), listed as active, not recruiting in its August 3, 2026 registry record.2
  • Registered trial without results A Phase 3 trial of cagrilintide alone in overweight or obesity (NCT07745504), listed as not yet recruiting in its August 4, 2026 registry record.11

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.4
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.4
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.4
Records collected

7 ClinicalTrials.gov records and 6 PubMed records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight, Heart and blood vessels, Liver4

Latest dated events
  1. FDA’s page on unapproved GLP-1 drugs, which says cagrilintide cannot be used in compounding, is updated, as shown by its content-current date.3
  2. REDEFINE 1 results for the cagrilintide-semaglutide combination are published in The New England Journal of Medicine.10
  3. Results of the Phase 2 cagrilintide trial are published in The Lancet.8
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.3
  2. DailyMed publishes the Wegovy label version cited on this page.4
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.12

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  3. 3
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  5. 5
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060 ↗

    The Lancet · Official source · Source checked November 14, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  11. 11
    ClinicalTrials.gov record NCT07745504 · retained source version 2026-08-04:624035118e08abe47d4c56faae694b0047f077f295c17f9043520d41dcfc3f70 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  12. 12
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026